Can a psychedelic compound ease suicidal thoughts in bipolar depression?

NCT ID NCT06706232

First seen Jul 30, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This phase 2 trial is investigating whether two doses of psilocybin (25 mg each, given 4 weeks apart) combined with psychotherapy are safe and acceptable for people with bipolar II disorder who are experiencing depression and suicidal thoughts. The study enrolls 10 adults aged 25–70 and measures feasibility, retention, and changes in suicidal ideation and depression scores. It aims to see if this approach could offer a new way to help those with treatment-resistant symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin (25 mg) given twice, 4 weeks apart, plus therapeutic support including preparatory and integration sessions
What this could lead to
If safe and acceptable, this approach could point toward a new treatment option for bipolar II depression with suicidal thoughts.
What could go wrong
This is a very small early-phase trial with only 10 participants, so results may not apply broadly. Psilocybin can cause intense psychological effects and is not yet proven safe in this population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR II DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The University of Texas Health Science Center at Houston

    RECRUITING

    Houston, Texas, 77006, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.